Mario Amatruda

Mario Amatruda

Auto-generated profile, based on publicly available information

Mario Amatruda

Research & Early Development, Dompé Farmaceutici S.p.A, Naples, Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2019 in eLife
Verified
Journal Article
Open access
VBValentina Bonnefil
Valentina Bonnefil
KDKaren Dietz
Karen Dietz
MAMario Amatruda
Mario Amatruda
MWMaureen Wentling
Maureen Wentling
AAAntonio V Aubry
Antonio V Aubry
JLJia Liu
Jia Liu
Exposure to stress increases the risk of developing mood disorders. While a subset of individuals displays vulnerability to stress, others remain resilient, but the molecular basis for these behavioral differences is not well understood. Using a model of chronic social defeat stress, we identified region-specific differences in myelination between mice that displayed social avoidance behavior (‘susceptible’) and those who escaped the deleterious effect to stress (‘resilient’). Myelin protein content in the nucleus accumbens was reduced in all mice exposed to stress, whereas decreased myelin thickness and internodal length were detected only in the medial prefrontal cortex (mPFC) of susceptible mice, with fewer mature oligodendrocytes and decreased heterochromatic histone marks. Focal demyelination in the mPFC was sufficient to decrease social preference, which was restored following new myelin formation. Together these data highlight the functional role of mPFC myelination as critical determinant of the avoidance response to traumatic social experiences.Editorial note: This article has been through an editorial process in which the authors decide how to respond to the issues raised during peer review. The Reviewing Editor's assessment is that all the issues have been addressed (see decision letter).

1 May 2019 in EBioMedicine
Verified
Journal Article
Open access
KCKamilah Castro
Kamilah Castro
ANAchilles Ntranos
Achilles Ntranos
MAMario Amatruda
Mario Amatruda
MPMaria Petracca
Maria Petracca
PKPeter Kosa
Peter Kosa
PCPatrizia Casaccia
Patrizia Casaccia
Multiple Sclerosis (MS) results from genetic predisposition and environmental variables, including elevated Body Mass Index (BMI) in early life. This study addresses the effect of BMI on the epigenome of monocytes and disease course in MS. Fifty-four therapy-naive Relapsing Remitting (RR) MS patients with high and normal BMI received clinical and MRI evaluation. Blood samples were immunophenotyped, and processed for unbiased plasma lipidomic profiling and genome-wide DNA methylation analysis of circulating monocytes. The main findings at baseline were validated in an independent cohort of 91 therapy-naïve RRMS patients. Disease course was evaluated by a two-year longitudinal follow up and mechanistic hypotheses tested in human cell cultures and in animal models of MS. Higher monocytic counts and plasma ceramides, and hypermethylation of genes involved in negative regulation of cell proliferation were detected in the high BMI group of MS patients compared to normal BMI. Ceramide treatment of monocytic cell cultures increased proliferation in a dose-dependent manner and was prevented by DNA methylation inhibitors. The high BMI group of MS patients showed a negative correlation between monocytic counts and brain volume. Those subjects at a two-year follow-up showed increased T1 lesion load, increased disease activity, and worsened clinical disability. Lastly, the relationship between body weight, monocytic infiltration, DNA methylation and disease course was validated in mouse models of MS. High BMI negatively impacts disease course in Multiple Sclerosis by modulating monocyte cell number through ceramide-induced DNA methylation of anti-proliferative genes. FUND: This work was supported by funds from the Friedman Brain Institute, NIH, and Multiple Sclerosis Society.

15 July 2019 in Brain
Verified
Journal Article
Closed access
MWMaureen Wentling
Maureen Wentling
CLCarlos López-Gómez
Carlos López-Gómez
HPHye-Jin Park
Hye-Jin Park
MAMario Amatruda
Mario Amatruda
ANAchilles Ntranos
Achilles Ntranos
PCPatrizia Casaccia
Patrizia Casaccia
Multiple sclerosis is an autoimmune demyelinating disorder of the CNS, characterized by inflammatory lesions and an underlying neurodegenerative process, which is more prominent in patients with progressive disease course. It has been proposed that mitochondrial dysfunction underlies neuronal damage, the precise mechanism by which this occurs remains uncertain. To investigate potential mechanisms of neurodegeneration, we conducted a functional screening of mitochondria in neurons exposed to the CSF of multiple sclerosis patients with a relapsing remitting (n = 15) or a progressive (secondary, n = 15 or primary, n = 14) disease course. Live-imaging of CSF-treated neurons, using a fluorescent mitochondrial tracer, identified mitochondrial elongation as a unique effect induced by the CSF from progressive patients. These morphological changes were associated with decreased activity of mitochondrial complexes I, III and IV and correlated with axonal damage. The effect of CSF treatment on the morphology of mitochondria was characterized by phosphorylation of serine 637 on the dynamin-related protein DRP1, a post-translational modification responsible for unopposed mitochondrial fusion in response to low glucose conditions. The effect of neuronal treatment with CSF from progressive patients was heat stable, thereby prompting us to conduct an unbiased exploratory lipidomic study that identified specific ceramide species as differentially abundant in the CSF of progressive patients compared to relapsing remitting multiple sclerosis. Treatment of neurons with medium supplemented with ceramides, induced a time-dependent increase of the transcripts levels of specific glucose and lactate transporters, which functionally resulted in progressively increased glucose uptake from the medium. Thus ceramide levels in the CSF of patients with progressive multiple sclerosis not only impaired mitochondrial respiration but also decreased the bioavailability of glucose by increasing its uptake. Importantly the neurotoxic effect of CSF treatment could be rescued by exogenous supplementation with glucose or lactate, presumably to compensate the inefficient fuel utilization. Together these data suggest a condition of ‘virtual hypoglycosis’ induced by the CSF of progressive patients in cultured neurons and suggest a critical temporal window of intervention for the rescue of the metabolic impairment of neuronal bioenergetics underlying neurodegeneration in multiple sclerosis patients.

20 January 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
EMEliza Mathias Melo
Eliza Mathias Melo
FRFilipe Resende
Filipe Resende
FAFernando Roque Ascenção
Fernando Roque Ascenção
CQCelso Martins Queiroz-Junior
Celso Martins Queiroz-Junior
MAMario Amatruda
Mario Amatruda
MTMauro Martins Teixeira
Mauro Martins Teixeira
Pulmonary inflammation is a central feature of several chronic lung diseases. The chemokine receptor CXCR2 plays a key role in regulating recruitment and activation of leukocytes and other cell types involved in acute and chronic inflammation of the lungs. In this study, we evaluated and compared the anti-inflammatory effects of four CXCR2 antagonists - DF2755A, AZD-5069, SX-682, and SCH527123 - in a murine model of bleomycin-induced lung injury. C57BL/6 mice received intranasal bleomycin and were treated once a day with known active doses of the antagonists by oral gavage. Following disease induction through bleomycin inoculation on day 0, animals were either treated at days 0-2 and then evaluated at day 2 (focus on the early inflammatory response) or treated from days 0-16 (preventive schedule) or from days 8-16 (therapeutic schedule) and then evaluated at day 16 (focus on fibrosis). We assessed inflammatory responses in bronchoalveolar lavage fluid (BALF) and lung tissue by analyzing total and differential leukocyte counts, cytokine levels, myeloperoxidase (MPO) activity, BALF protein content, and lung histopathology. All compounds displayed anti-inflammatory effects (day 2), with DF2755A and AZD-5069 standing out for their greater efficacy in reducing early neutrophils influx. Importantly, DF2755A and SX-682 were particularly effective in mitigating fibrosis and chronic inflammatory changes when administered in both preventive and therapeutic schedules, even at later stages of disease progression. These findings underscore the potential of CXCR2 antagonism, especially with DF2755A, as a promising strategy to limit inflammation and fibrosis in experimental lung injury.